share_log

CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SEC announcement ·  Feb 21 20:50
Summary by Futu AI
On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared...Show More
On February 21, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the year ended December 31, 2023, along with other business highlights. The announcement included the approval of CASGEVY™ in multiple regions for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT), and the progress of clinical trials for several product candidates, including CTX112™ and CTX131™ targeting CD19 and CD70, and in vivo gene editing candidates CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a). The company also reported on the ongoing clinical trial for CTX211™ for Type 1 Diabetes (T1D) treatment. CRISPR Therapeutics strengthened its balance sheet with a $280 million registered direct offering, bringing its current cash position to over $2.1 billion. The financial results showed a net income of $89.3 million for the fourth quarter of 2023, compared to a net loss of $110.6 million for the same period in 2022. Cash, cash equivalents, and marketable securities were reported at $1,695.7 million as of December 31, 2023. The company's CEO, Samarth Kulkarni, Ph.D., expressed excitement for the upcoming year with a focus on continuing to innovate and execute clinical trials across various therapeutic areas.

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.